City
Epaper

WHO flags three contaminated cough syrups in India, including Coldrif

By IANS | Updated: October 14, 2025 09:30 IST

New Delhi, Oct 14 The World Health Organisation (WHO) has identified three adulterated syrups manufactured in India, including ...

Open in App

New Delhi, Oct 14 The World Health Organisation (WHO) has identified three adulterated syrups manufactured in India, including the infamous Coldrif cough syrup, and has urged authorities worldwide to report to the agency if any of these products are detected in their respective countries.

The development comes weeks after the deaths of several children in Madhya Pradesh, linked to the consumption of adulterated cough syrup.

Among the three contaminated syrups flagged by WHO is Coldrif, which recently triggered widespread outrage following the children's deaths.

The global health body has identified specific batches of Coldrif from Sresan Pharmaceuticals, Respifresh TR from Rednex Pharmaceuticals, and ReLife from Shape Pharma as the affected medicines.

WHO warned that the identified syrups could cause severe and potentially life-threatening illnesses.

The Coldrif syrup, manufactured in Tamil Nadu, sparked major alarm after it was found to be dangerously contaminated with the toxic chemical diethylene glycol (DEG).

Tests revealed DEG concentrations exceeding 48 per cent -- an alarming figure far above the permissible limit of 0.1 per cent.

Following this, Sresan Pharmaceuticals had its manufacturing license revoked, and its owner, G. Ranganathan, was arrested.

The authorities also ordered a comprehensive inspection of other drug manufacturing companies across the southern state to identify potential lapses in quality control.

The deaths of children in Madhya Pradesh prompted the Central government to issue an advisory to all states and union territories, urging extreme caution in the prescription of cough syrups for children.

The advisory specifically stated that such medications should not be prescribed or dispensed to children below two years of age and are generally not recommended for those under five.

Health officials have emphasised that the incident highlights the urgent need for stricter regulatory oversight of pharmaceutical manufacturing in the country to prevent similar tragedies.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

BusinessAsia's premier pro boxing championship Global Boxing Series in association with IBA returns this April 26th at Nexus Seawoods Navi Mumbai

BusinessNemetschek India Unveils 'UNBOUND' Mumbai 2026 to Scale AI Integration and Seamless Collaboration in India's Construction Industry

BusinessMayabious Group wins four metals at the Economic Times Award for Design and Creativity

NationalAmaravati set to emerge as India's first Quantum Reference Facility

NationalPunjab seeks special relief from centre: State agriculture minister Gurmeet Khudia

National Realted Stories

NationalElection Commission files FIR against Trinamool's Nandigram candidate Pabitra Kar

NationalFICCI urges steps to cut industry risks amid West Asia crisis​

NationalModerate rain likely in Tamil Nadu for next seven days, thunderstorms expected in several regions

NationalUttarakhand CM Dhami attends Gaurav Sainik Samman Samaroh; pays floral tribute to late father

NationalTelangana HC reserves order on Pawan Khera's transit anticipatory bail petition